May 23, 2017 7:51am
Insight is also about putting into context what is relevant to expectation fulfillment
The take-away, don’t dwell on what’s happened but, learn the lesson of investing in those who define and meet short-term expectation
Spare the sell call, ruin the portfolio
Higher open expected
Companies in my headlights: six (6), 2 BUYS and 4 SELLS
.
Critical information ahead of “our” universe’s open! I provide intelligence and analysis for short and near-term investment.
Expectation is the word for 2017 – meeting the unknowns with the soon to be exposed concerns will be the subject of investing decisions throughout this year.
Dow futures are UP +0.23% and NASDAQ futures are UP +0.20%
U.S. stock index futures pointed to a higher open on Tuesday, as investors geared up for more news out of Donald Trump's first overseas trip as president, while keeping an eye on the moves in oil
European markets turned higher as investors digested fresh economic data in the euro zone after waking up to news of another suspected terrorist incident in the U.K.
Asian markets closed mostly lower after trading sideways for most of Tuesday, despite major Wall Street indexes closing in the green, as news of a deadly bombing at a concert venue in Manchester weighed sentiment.
Data docket: IHS Markit Flash US Composite PMI data will also be released at 9.45 a.m. ET.
The cell therapy sector closed NEGATIVE on Monday, POSITIVE on Friday and Thursday, NEGATIVE on Wednesday and POSITIVE on last Tuesday
The cell therapy sector’s record after the last 5 days (of 43 covered companies):
· Monday closed NEGATIVE with 21 decliners, 19 advancers and 3 flats;
· Friday closed POSITIVE with 15 decliners, 26 advancers and 2 flat;
· Thursday closed POSITIVE with 13 decliners, 25 advancers and 5 flats;
· Wednesday closed NEGATIVE with 38 decliners, 5 advances and 0 flats;
· Last Tuesday closed POSITIVE with 19 decliners, 23 advancers and 1 flat;
Remembering Monday’s closing bell newsletter, “Falling sector, needs to seek cover.”
- Reiterating, “The sector is what it is, until it isn’t and even then it doesn’t seem to be…”
Spin and puffery have a long history in share pricing, but something has snapped with investors who no longer expect managements to talk straight. We have become immune to hype and the story makers who expound it.
- William Safire used to defend his language with a dissection of both “congenital” and “liar.” He cited Winston Churchill, who had once chided a colleague for “terminological inexactitude,” before quoting Churchill’s advice that “short words are best, and the old words when short are best of all.”
Our perception keeps getting in the way. A downside of the “our” universe is a believing the written word from companies and their PR shrills.
- Nobody “watches” anything anymore, they “monitor” it.
No action is taken until all “stakeholders” are consulted. We say “price point” when we mean “price.” And is there no other way to express sympathy besides pledging “thoughts and prayers”?
- This lament is not about semantics.
It is about the urgent ... need for plain honesty with investors. Being politically correct is not always being ethically correct. It is being dishonest and investors are suffering the consequences.
But, outright … lies are still fabrications especially when they relate to the status of a company’s delisting as MANY other legal ISSUES are JUST below the reading glasses i just look at Biostage (BSTG)!
And many “x”s (former employees) are keeping the list and will have a LOT to say …!!
Journalists have a DUTY and analysts have to certify in telling the TRUTH!!
What did I see on Monday, the DOW closed up +0.43% (+89.99) and The NASDAQ closed UP + 0.82% (+49.92) while volatility traded at 10.9.
The count - gainers: look at the differences in the spreads and advance/decline lines – look at how the numbers define volatility:
- Friday’s decliners ranged from -0.17% <BSTG> to -6.78% <BLUE> in 15 equities;
- Monday’s decliners ranged from -0.45% <BLFS> to -21.67% <BSTG> in 21 equities;
While gainers ...
- Monday’s gainers ranged from +0.28% <RGNX> to +12.77% <OPXA> in 19 equities;
- Friday’s gainers ranged from +0.01% <HSGX> to +10.66% <QURE> in 26 equities;
You’ve made it to the office, turned on the monitor, having just gotten your coffee and it hits you - what could be today’s trades?
Watch list:
- The iShares Nasdaq Biotechnology (IBB) closed up +0.30% on Monday, and is NOT indicating a in Tuesday’s pre-market;
- The SPDR S&P Biotech ETF (XBI) closed Monday up +0.68%, and is NOT indicating in Tuesday pre-market;
- The Health Care Select Sector SPDR ETF (XLV) closed up +0.27% Monday, and is indicating a positive +0.03% in Tuesday’s pre-open;
- The iShares Russell 2000 (IWM) closed up +0.68% on Monday, and is indicating a positive +0.21% in Tuesday’s pre-open
Companies in my headlights:
Applied Genetic Technologies (AGTC) closed up +$0.15 to $5.40. The aftermarket indication was -$0.15 or -2.78% - SELL;
Bellicum Pharmaceuticals (BLCM) closed down -$0.25 to $12.35. The aftermarket indication is a negative -$0.04 or -0.35% - SELL;
bluebird bio (BLUE) closed down -$3.50 to $78.95 and the aftermarket indication is a positive +0.19 or +0.25% - BUY;
Kite Pharma (KITE) closed up +$0.86 to $71.57. The aftermarket indication is a positive +$0.23 or +0.32% - BUY;
Sangamo (SGMO) closed down -$0.35 to $7.45. The aftermarket indication is a positive +$0.15 or +1.92% - BUY;
Vericel closed flat at $2.65. The aftermarket indication is a positive +$0.05 or +1.89% - BUY;
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
Henry’s comments are for informational purposes only and are not a substitute for personalized advice. Consult your advisor about what is best for you.
